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ABSTRACT 
The nuclear receptors CAR (constitutive androstane receptor) and possibly PXR (pregnane 
X receptor) mediate the hepatic effects of phenobarbital (PB) and similarly-acting compounds. 
Although PB is a potent non-genotoxic tumor promoter in rodent liver, epidemiological data 
from epilepsy patients treated with phenobarbital do not show a specific role of PB in human 
liver cancer risk. That points to species differences in the susceptibility to tumor promotion by 
PB, which might be attributed to divergent functions of the PB receptors CAR and PXR in 
mice and humans. In the present study, male transgenic mice expressing human CAR and 
PXR were used to detect possible differences between wild type and humanized mice in their 
response to CAR activation in a tumor initiation/promotion experiment with a single injection 
of the tumor initiator N-nitrosodiethylamine preceding chronic PB treatment for 10 months. 
Analysis of liver tumor burden revealed that PB strongly promoted the outgrowth of 
hepatocellular adenoma driven by activated β-catenin in wild type mice, whereas the tumor-
promoting effect of PB was much less pronounced in the humanized group. In conclusion, 
the present findings demonstrate that human CAR and PXR support tumor promotion by PB 
in mouse liver, but to a significantly lesser extent than the wild type murine receptors. 
 
 
 
 
 
Key words: liver tumor; non-genotoxic carcinogen; HCC; constitutive androstane receptor; 
pregnane X receptor 
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INTRODUCTION 
Phenobarbital (PB), also known as phenobarbitone, is a long-acting barbiturate that 
has been used in human medicine mainly as anticonvulsant, often in combination with 
phenytoin and other therapeutics. PB is a well-established non-genotoxic hepatocarcinogen 
in rodents (Lee, 2000; Whysner et al., 1996) and there is toxicological concern about the 
relevance of this tumor-promoting effect for humans. Several large epidemiological studies 
on epileptics who received prolonged treatment with PB, phenytoin and other anticonvulsants 
have been conducted which, on the one hand, have provided little evidence that PB and 
phenytoin are carcinogenic to humans, but cannot, on the other hand, rule out this possibility 
(Clemmesen and Hjalgrim-Jensen, 1978; Lamminpaa et al., 2002; Olsen et al., 1989; Olsen 
et al., 1995). 
The precise mechanism of the liver tumor promoting activity of PB in rodents is not 
fully understood. The experimental evidence points towards a possible role of PB interfering 
with gap junction-mediated intercellular communication since the liver tumor promotional 
activity of the barbiturate is lost in mice deficient for connexin32, the major gap junctional 
protein in mouse liver (Moennikes et al., 2000). A second important protein clearly involved in 
liver tumor promotion in mice is β-catenin: PB strongly selects during the promotional phase 
for hepatocytes carrying activating mutations of the Ctnnb1 gene, encoding a mutant and 
constitutively activated version of the transcription factor β-catenin (Aydinlik et al., 2001). The 
conditional knockout of Ctnnb1 in mouse hepatocytes eradicates PB-mediated tumor 
promotion (Rignall et al., 2011). A third important mechanism is the activation of nuclear 
receptors: PB activates the constitutive androstane receptor (CAR) and, to a lesser extent, 
also the pregnane X receptor (PXR). CAR plays a pivotal role in the tumor promotional 
activity of PB, since the emergence of liver tumors can no longer be promoted by PB in CAR-
deficient mice (Yamamoto et al., 2004). Finally, liver tumor susceptibility factors play an 
important role: mice of strains with high susceptibility to chemically induced 
hepatocarcinogenesis and a high prevalence of spontaneous liver tumors, such as C3H or 
B6C3F1, are also more susceptible to PB-mediated tumor promotion than mice of resistant 
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strains, such as C57BL (Bursch et al., 2004; Diwan et al., 1986; Jones et al., 2009). The lack 
of a significant carcinogenic effect of PB in humans may thus have different reasons: (1) due 
to toxicokinetic reasons, the human PB dose level at the therapeutic dose (1-4 mg/kg body 
weight per day; Lagenstein, 1983) may be too low to produce the significant carcinogenic 
effects seen in rodents, where daily dose levels >80mg/kg body weight are generally used in 
rodent initiation/promotion studies. (2) Alternatively, toxicodynamic differences may render 
humans less susceptible to the tumor promoting effects of PB. One of the reasons for 
reduced susceptibility of humans could be related to differences in the structure and function 
of the human CAR/PXR relative to the murine receptors. However, we have very recently 
published the results of a study where the transcriptional as well as the proliferative 
responses to PB were studied in a double humanized (CARh-PXRh) mouse model and only 
minor differences in response were observed when compared to those of wildtype mice 
(Luisier et al., 2014). We have now used the same strains of CARh-PXRh and wildtype mice 
to comparatively investigate the tumor promoting efficacy of PB in a long-term 
initiation/promotion study. The results of the study demonstrate that liver tumor formation can 
be promoted by PB in both wildtype and CARh-PXRh humanized mice, but to a significantly 
lesser extent in the humanized model.  
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MATERIALS AND METHODS 
 Animal experiments. Male C57BL/6-Nr1i2tm1(NR1I2)ArteNr1i3tm1(NR1I3)Arte mice expressing 
human CAR and PXR (in the following referred to as hCAR/hPXR mice) and wild type (WT) 
C57BL/6 control mice were purchased from Taconic (Cologne, Germany). The animals (15 
mice per each of the four groups; i.e. WT, WT plus phenobarbital, hCAR/hPXR, hCAR/hPXR 
plus phenobarbital) were kept individually in type II long cages and received a single 
intraperitoneal injection of 90mg/kg body weight N-diethylnitrosamine (DEN; dissolved in 
0.9% NaCl solution) at 6 weeks of age. Starting one week later, mice were fed either control 
diet or a diet containing 0.05% (w/v) phenobarbital (Ssniff, Soest, Germany) for 40 weeks. 
For this purpose, phenobarbital (Sigma, Taufkirchen, Germany) had been incorporated into a 
rat/mouse maintenance diet (Ssniff; catalog no. V1534) via a premixture. Mice had access to 
food and tap water ad libitum. They were kept at 22±2°C room temperature and 55±10% 
relative humidity on a 12h dark/light cycle and sacrificed in a time window between 9 and 11 
a.m. to avoid circadian variations. For analysis of short term DEN effects, two additional mice 
of each genotype were injected with DEN as described above and sacrificed 3h later. 
Following sacrifice, livers were excised, weighed, and immediately frozen on dry ice. A 
schematic representation of the animal experiments is presented in Figure 1. Animal weight 
was initially assessed on a weekly basis, with an extension of the intervals to 4 weeks 
towards the end of the study. Mice were inspected daily for overall appearance, posture, and 
motion. Animals received humane care and protocols complied with institutional guidelines. 
 Histology and immunostaining. Cryostat sections (10µm thickness) were used for 
all stainings. O6-ethylguanine was visualized following fixation in -20°C methanol for 30min 
using an antibody against O6-ethylguanine (1:500 dilution; gift from Dr. J. Thomale, Essen, 
Germany) in combination with a Cy3-conjugated goat anti-mouse secondary antibody (1:100; 
Dianova, Hamburg, Germany) according to the methodology described previously (Rignall et 
al., 2011). Immunohistochemical staining of glutamine synthetase (GS) was carried out on 
formaldehyde-fixed slices according to standard methods (Braeuning et al., 2010), using a 
primary antibody against GS (1:1000; Sigma) together with an appropriate horseradish 
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peroxidase (HRP)-conjugated secondary antibody (1:100; Dako, Glostrup, Denmark) with 3-
amino-9-ethylcarbazole/H2O2 as substrates. Nuclei were counterstained by hematoxylin. 
Histochemical staining for glucose-6-phosphatase activity was performed according to 
Wachstein and Meisel (1957). 
 Tumor quantification. Liver tumor burden was measured as the area fraction 
(equivalent to the volume fraction) of glucose-6-phosphatase-altered lesions using an Axio 
Imager light microscope (Imager.M1; Zeiss, Göttingen, Germany) with AxioVision software 
Rel.4.5 (Zeiss). Number and size of glucose-6-phosphatase lesions per cm3 of liver tissue 
were calculated according to Campbell et al. (1982). For each mouse, the right, left lateral, 
and caudate lobes of the liver were analyzed using three slices per liver lobe with at least 20 
sections distance between the individual slices. Immunohistochemical staining for GS and E-
cadherin was assessed on parallel slices. 
  Mutation analysis. Tumor tissue samples were punched out of GS-stained cryostat 
sections by the use of a sharpened cannula as previously described (Braeuning et al., 2010). 
Following proteinase K digestion of the isolates, a 248bp fragment of the Ctnnb1 gene 
containing the mutation hotspots in exon 3 was amplified by PCR using the primer pair 
Ctnnb1-fwd: 5’-ACTCTGTTTTTACAGCTGACC-3’ and Ctnnb1_rev: 5’-
TTTACCAGCTACTTGCTCTTG-3’ (rev). PCR products were analyzed for mutations by 
dideoxy sequencing of both strands. 
 Preparation of hepatic microsomal fractions. Microsomes were prepared from 
snap frozen liver tissue (3 pools of 3-4 mice per genotype/treatment) as previously described 
(Meehan et al., 1988). Microsomes were stored at -70˚C until required. Microsomal protein 
concentrations were determined using the Biorad Protein Assay Reagent (Bio-Rad Labs, 
Herts, UK).   
 Immunoblotting. Immunoblot analysis was carried as previously described using 
polyclonal antisera raised against human POR (Smith et al., 1994), rat cytochrome P450 
(CYP) 2B1, CYP2C6, CYP3A1, and CYP2D1 (Forrester et al., 1992). 15µg of hepatic 
microsomal protein was loaded per lane, and recombinant POR, CYP2B10, CYP2C9, 
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CYP2D22, and CYP3A11 proteins generated in house were used as standards. 
Immunoreactive proteins were detected using polyclonal goat anti-rabbit HRP-conjugated 
immunoglobulins as secondary antibody (Dako, Ely, UK), and visualized using Immobilon 
chemiluminescent HRP substrate (Millipore, Watford, UK) and a FUJIFILM LAS-3000 mini 
imaging system (Fujifilm UK, UK).  GRP78 was used as a loading control. Densitometric 
analysis was performed using Multi Gauge V2.2 software (Fujifilm UK).   
 Gene expression analysis. Trizol reagent (Life technologies, Darmstadt, Germany) 
was used to isolate total RNA, which was transcribed by avian myeloblastosis virus reverse 
transcriptase (Promega, Mannheim, Germany) as previously described (Ganzenberg et al., 
2013). Gene expression analyses were carried out on a LightCycler system by the use of the 
FastStart DNA master SYBR Green I kit (Roche, Mannheim, Germany) and the following 
primer pairs: 18s rRNA_fwd 5’-CGGCTACCACATCCAAGGAA-3’; 18s rRNA_rev 5’-
GCTGGAATTACCGCGGCT-3’; Cyp2b10_fwd 5’-TACTCCTATTCCATGTCTCCAAA-3’; 
Cyp2b10_rev 5’-TCCAGAAGTCTCTTTTCACATGT-3’; Cyp2c_fwd 5’-
CTCCCTCCTGGCCCCAC-3’; Cyp2c_rev 5’-GGAGCACAGCTCAGGATGAA-3’; Cyp2d_fwd 
5’-GACATCCCGTGACATCGAAGTAC-3’; Cyp2d_rev 5’- 
CAGCAGGGAGGTGAAGAAGAGG-3’; Cyp3a_fwd 5’-TCACAGCCCAGTCAATTATCTT-3’; 
Cyp3a_rev 5’-GGAATCATCACTGTTGACCCT-3’. Values were normalized to the expression 
of the housekeeping gene 18s rRNA according to Pfaffl (2001). 
  Phenobarbital determination. The concentration of phenobarbital in mouse liver 
homogenate was measured by protein precipitation followed by reverse phase LC-MS/MS. 
Mouse liver homogenates were prepared by weighing mouse livers and preparing a 1 in 5 
homogenate with milli-Q deionized water. Standards were prepared by adding a series of 
phenobarbital solutions to blank control mouse liver homogenates. The samples and 
standards (100µl) were extracted with acetonitrile (400µl), then centrifuged at 13,000 rpm for 
10 minutes. 50µl of the supernatant was transferred to 96 well plates and diluted with 200µl 
50/50 (v/v) acetonitrile/water. The samples were injected onto a Shimadzu UFLC-20AD 
System coupled to an ABSciex Triple Quad 6500 Mass Spectrometer. The mass 
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spectrometer was operated in electrospray, negative ion mode and the MRM transition 
230.989>187.000 was monitored. The UFLC column was Kinetex C18XB 50 x 2.1mm, 2.6µm, 
maintained at 40°C. Mobile phase A was 10mM ammonium formate in water and mobile 
phase B was 0.1% formic acid in acetonitrile. A gradient was run from 20% mobile phase B 
to 98% mobile phase B over 0.3 minutes and held at 98% mobile phase B until 1.2 minutes, 
at a flow rate of 0.55ml/min. The total run time was 2 minutes. Linearity was demonstrated 
over the range 0.05-10µg/ml in mouse liver homogenate. 
 Statistical analysis. For analysis of possible genotype and/or treatment effects 
ANOVA analyses with Bonferroni’s correction were performed using GraphPad Prism 
Software (Graph Pad Software, La Jolla, CA, USA). Hepatic PB level data were analyzed 
using Student’s t-test. Differences were considered significant when p<0.05. 
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RESULTS 
 
Animal and organ weight 
Mice were given a single i.p. injection of DEN at 6 weeks of age, followed by 40 weeks of 
tumor promotion by PB (Figure 1). In the absence of PB, body weight gain of the animals 
throughout the experiment did not significantly differ between the two genotypes. However, it 
was slightly different between the WT and hCAR/hPXR groups in the presence of the tumor 
promoter (Figure 2A): on the one hand, PB-treated WT mice exhibited a more pronounced 
weight gain than controls, whereas, on the other hand, the body weight of PB-treated 
hCAR/hPXR mice remained lower than that of non-PB-treated hCAR/hPXR mice. Thus, body 
weight of PB-treated WT mice was significantly higher, as compared to PB-treated 
hCAR/hPXR mice throughout the second half of the experiment (Figure 2A; values at the end 
of the experiment: WT+PB: 38.1g ±1.1g, hCAR/hPXR+PB: 35.4g ±0.8g). However, even 
though statistically significant, animals did not show signs of toxicity or illness, indicating that 
this finding might not be of major biological relevance. PB significantly increased the liver to 
body weight ratio in both genotypes (Figure 2B). The mean relative liver weight of 
hCAR/hPXR mice was significantly higher, as compared to WT animals, in both the non-PB 
(6.28% vs. 5.53% of body weight) and the PB (8.55% vs. 7.72%) group (Figure 2B). Lipid 
droplet accumulation was observed in PB-treated mice from both genotypes, with the more 
pronounced effect observed in hCAR/hPXR mice (Figure 2C; see also images in Figure 5).  
Expression and induction of CAR target genes 
Expression of model CAR target genes related to drug-metabolism enzymes was assessed 
at the mRNA and protein levels. The mRNAs encoding the CYP isoforms 2b10, 2c, and 3a 
were expressed at higher basal levels in hCAR/hPXR mice (Figure 3A). Induction upon PB 
treatment was seen in both genotypes. Cyp2b10 (and, slightly failing our criteria for statistical 
significance, Cyp2c) was induced up to higher levels in WT as compared to hCAR/hPXR 
mice by PB. By contrast, Cyp3a induction by PB was weak in WT mice, whereas a very 
pronounced response was observed in the humanized mice (Figure 3A). Induction of CYPs 
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by PB was also detected by Western blotting. CYP2B and CYP2C proteins were comparably 
induced by PB in mice from both genotypes. Resembling the mRNA results, CYP3A 
induction was stronger in the humanized mice (Figure 3B). 
 
Tumor quantification 
Tumor burden of WT and hCAR/hPXR mice was quantified. In the absence of PB, the liver 
tumor incidence was 46.7% (7 out of 15) in WT and 80% (12/15) and in hCAR/hPXR mice. 
Treatment with PB increased the tumor incidence to 100% (14/14 and 15/15, respectively) in 
mice from both genotypes. The hepatic tumor volume fraction, measured as G6Pase-altered 
lesions, was below 0.25% in the non-PB groups, irrespective of the genotype. Treatment with 
PB led to elevated mean hepatic tumor volume fractions in both WT (6.53%) and 
hCAR/hPXR (2.25%) mice (Figure 4A), an effect which was statistically significant for WT, 
but not for hCAR/hPXR mice. Tumor burden of PB-treated WT mice was significantly higher 
than tumor burden of PB-treated hCAR/hPXR mice (Figure 4A). The calculated liver tumor 
multiplicity was low in the non-PB groups and significantly elevated upon PB treatment in 
mice from both genotypes (Figure 4B). Again, the values obtained for the PB-treated WT 
group were significantly higher than for the PB-treated hCAR/hPXR group (123 lesions/cm3 
vs. 64 lesions/cm3; Figure 4B). Grouping of tumors according to their size revealed that the 
appearance of very small lesions (<0.5mm in diameter) was significantly induced by PB in 
both genotypes, without statistically significant differences between humanized mice and 
controls (Figure 4C). The incidence of medium size tumors with diameters between 0.5mm 
and 1.6mm was also significantly increased by PB in mice from both genotypes, but the 
response of WT mice was significantly more pronounced, as compared to hCAR/hPXR mice 
(Figure 4C). Similarly, large tumors (>1.6mm) were significantly more frequent in PB-treated 
WT mice, as compared to WT controls, whereas no such significant increase was seen in 
hCAR/hPXR mice treated with PB (Figure 4C).  
Phenotypically, the vast majority of tumors (>90%) in livers of mice from both genotypes 
were eosinophilic, glutamine synthetase-positive well-differentiated hepatocellular adenoma 
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(Figure 5). This tumor phenotype is indicative of an activation of the Wnt/β-catenin signaling 
pathway and expected for a protocol that consists of treatment of 6 weeks old mice 
according an established DEN/PB regimen (Aydinlik et al., 2001; Hailfinger et al., 2006). A 
minor fraction of tumors were basophilic, glutamine synthetase-negative hepatocellular 
adenoma. No carcinomas were observed in the study. To validate the activation of the β-
catenin in the tumors, mutation analyses for Ctnnb1 (encoding β-catenin) were conducted.  
Tumors were randomly chosen from PB-treated animals and analyzed as described in the 
methods section. As expected, activating mutations in exon 3 of Ctnnb1 were detected at 
high frequency in tumors from both genotypes, demonstrating that PB promotes the growth 
of same type of tumors in WT and hCAR/hPXR mice (Table 1). 
 
DNA adduct formation by DEN 
The different response of WT and hCAR/hPXR mice might be, in principle, due to differences 
in either the tumor initiation or tumor promotion process. To exclude an influence of initiation, 
formation of O6-ethylguanine, a major DNA adduct formed by DEN, in mouse livers of both 
genotypes was analyzed 3h after administration of DEN. As evident from Figure 6, O6-
ethylguanine was detected in perivenous hepatocytes. This is consistent with previous 
findings (Rignall et al., 2011) and with the theory of a preferential perivenous metabolic 
activation of DEN by perivenously-expressed cytochrome P450 enzymes. No remarkable 
differences between WT and hCAR/hPXR mice were observed regarding the formation of 
O6-ethylguanine (Figure 6). 
 
Analysis of hepatic PB levels 
It has been recently shown that administration of PB to hCAR/hPXR mice via the drinking 
water for up to 91 days leads to slightly elevated levels of PB in liver tissue of these mice, as 
compared to WT controls (Luisier et al., 2014). Therefore, tissue levels of PB were also 
analyzed in livers from WT and humanized mice from the present study. Indeed, the mean 
hepatic PB levels were significantly higher in mice with humanized CAR/PXR (20.6µg/g liver 
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vs. 11.9µg/g liver; Figure 7A). These data allowed us to normalize the tumorigenic response 
of each animal to its individual hepatic PB levels (Figure 7B). Based on this correlation, the 
overall difference in tumor response between mice of the two genotypes becomes even more 
obvious. In WT animals, PB tissue levels modestly correlated with hepatic tumor volume 
fraction (correlation coefficient r2=0.40; p=0.02), whereas no such correlation was visible in 
the hCAR/hPXR group. 
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DISCUSSION 
The present data demonstrate pronounced tumor promotion by PB in WT mice. Tumor 
response in our experiment closely resembles findings from a previous study conducted in 
our laboratory, where mice with similar genetic background had been treated according to 
the same protocol, resulting in a hepatic tumor volume fraction of approximately 5% (present 
study: 6.5%) and a tumor multiplicity of approximately 100 lesions/cm3 (present study: 
123/cm3) after 36 weeks of tumor promotion (Marx-Stoelting et al., 2009). Tumor response in 
PB-treated hCAR/hPXR mice was significantly less pronounced, regarding tumor volume 
fraction as well as tumor multiplicity. Furthermore, size class distribution of tumors shows that 
the most pronounced genotype differences are observed in the medium and large tumor size 
classes. Altogether, these data consistently indicate a reduction of tumor promotional activity 
of PB in the hCAR/hPXR model. 
While being a potent liver tumor promoter in rodents, epidemiological data do not provide 
sufficient evidence for a liver tumor-promoting effect of PB in humans (see introduction). The 
present data demonstrate that liver tumor promotion by PB is significantly more pronounced 
in WT mice, as compared to transgenic mice which express the human versions of the 
nuclear receptors CAR and PXR. This is rather surprising, since in a recent study dealing 
with PB effects in hCAR/hPXR mice following shorter exposure times (and in the absence of 
the tumor initiator DEN), no fundamental differences between the response of WT and the 
receptor-humanized mice were detected regarding the induction of CAR/PXR downstream 
genes related to drug metabolism or hepatocyte proliferation when exposed to different 
doses of PB via the drinking water for up to 90 days (Luisier et al., 2014). This was also the 
case in the present study. These results are, however, at variance with another study, which 
did not detect a proliferative response of hCAR hepatocytes following administration of PB 
after intraperitoneal administration of PB at a dose of 80mg/kg body weight per day for 4 
days (Ross et al., 2010). Similarly, sulfoxaflor treatment of mice for 7 days resulted in a slight 
increase in hepatocellular proliferation in WT, but not in hCAR/hPXR mice (LeBaron et al., 
2013). The reasons for this discrepancy are not fully understood: In the case of sulfoxaflor, 
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differences in the affinity of the compound for mouse and human CAR might exist which 
have influenced the outcome of the study. However, in the case of PB, neither the different 
routes of administration nor the rather slight differences in dosing and duration can serve as 
an obvious explanation. A more recent study from the same laboratory, using an alternate 
route of administration (0.1% PB in the diet for 7 days) to generate higher systemic exposure 
revealed that hCAR/hPXR mice respond to PB with hepatocellular replicative DNA synthesis 
(discussed in Luisier et al. (2014)). Nonetheless, the short-term effects of PB, i.e. hepatocyte 
hypertrophy, induction of drug-metabolizing enzymes, and transient hyperplasia of the liver, 
are not necessarily good quantitative surrogates for a tumor-promoting activity. This is 
evident from the comparison of tumor promotion (higher in WT mice) and drug metabolism 
induction (slight differences between genotypes, but in principle similar) in the present study, 
as well as from the comparison of the data in Luisier et al. (2014) with the present data on 
tumor promotion. PB selects for the outgrowth of liver tumors with mutationally activated β-
catenin (Aydinlik et al., 2001); accordingly, tumor formation in mice with a conditional 
hepatocyte-specific knockout of the β-catenin gene Ctnnb1 cannot be promoted by PB 
(Rignall et al., 2011). However, a considerable induction of drug-metabolizing enzymes by 
PB can be achieved in these mice (Braeuning et al., 2011; Braeuning et al., 2009). Moreover, 
the regulation of CYP induction and proliferation by PB is uncoupled in mice with hepatocyte-
specific knockout of Ctnnb1 (Braeuning et al., 2011).  
This study for the first time provides clear evidence that species differences in the receptors 
CAR and/or PXR affect tumor promotion by PB in the liver. The observed differences 
become even more pronounced when the data are normalized to hepatic PB levels, which 
were higher in hCAR/hPXR mice as compared to WT animals. This view assumes that the 
two PB tissue concentrations are below the plateau of the biological response to PB, an 
assumption which is substantiated by the results on CYP induction in the recent study by 
Geter et al. (2014), where PB was administered at different doses for up to 7 days. The 
reason for the different hepatic PB levels is not known. In principle, it might be related either 
to a differential intake of PB, or to differences in metabolism and/or elimination. The first 
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scenario would imply an increased food intake of the hCAR/hPXR mice. This cannot be fully 
excluded, since food uptake has not been measured in the present study. However, the fact 
that hCAR/hPXR mice treated with PB gained weight slightly slower than their WT 
counterparts suggests that the hCAR/hPXR mice most likely did not consume significantly 
more food than the mice from the WT+PB group. Therefore, the differences are most likely to 
be attributed to metabolism or excretion. However, the rather minor alterations in CYP 
expression between the two genotypes do not provide clear evidence for major differences in 
PB metabolism.  
To estimate a possible human risk, exposure levels of mice and humans have to be 
compared (Table 2). Food intake was not measured in the present study. Therefore, the 
exact dose of PB of the animals is not known. However, based on published data, C57BL/6 
mice consume approximately 5g of diet per 30g mouse and day (Bachmanov et al., 2002). 
From this we can calculate an average PB dose of approximately 80mg/kg body weight per 
day for the mice in our present study (PB concentration 0.05% in diet). The human exposure 
at the therapeutic level is 1-4mg/kg body weight per day. At first glance, this suggests a large 
difference in exposure level. However, when scaled allometrically, the murine dose of 
80mg/kg body weight per day equals a human dose of approximately 11.5mg/kg body weight 
per day, which is not much higher than therapeutic dosage. With respect to biological activity 
in the liver, serum and liver tissue concentrations of PB are the more relevant measures for 
comparison. The mean liver concentrations of PB in the present study were 11.9µg/g liver in 
WT mice and 20.6µg/g in hCAR/hPXR mice. PB serum levels were not determined. However, 
in a recent study (Luisier et al., 2014), where PB was given in drinking water at a 
concentration of 0.05% to mice of the same strain, average liver levels at steady state in WT 
mice were 15.1µg/g and average serum levels were 17.8µg/ml. Similar serum levels of 
approximately 15µg/ml were observed in male CD1 mice given PB via the diet at a level of 
75mg/kg body weight per day (Geter et al., 2014). For comparison, the therapeutic steady 
state serum level of PB as an anticonvulsant in humans is commonly reported as 15-70µg/ml 
(e.g. see Houghton et al. (1975)). We were not able to find data on human PB liver levels at 
 at U
niversity of D
undee on Septem
ber 29, 2016
http://toxsci.oxfordjournals.org/
D
ow
nloaded from
 
the therapeutic dose, but, based on the reported partition coefficient of liver/serum of 2.25 in 
humans (El-Masri and Portier, 1998), the liver steady state levels would be approximately 
two-fold those of the serum level. This indicates that the serum and liver levels in humans at 
the therapeutic dose are in the same range or even higher than those observed in the mouse 
treated with a dose of PB where tumor promotional activity of the drug is seen. In fact, short-
term effects of PB comparable to those observed in the mouse have been reported also for 
humans, i.e. the induction in the levels and activities of drug-metabolizing enzymes in livers 
of epileptics (Sotaniemi et al., 1978) as well as in cultured primary human hepatocytes 
(Madan et al., 2003).  
In summary, the present data do not absolve PB of being a tumor promoter with possible 
relevance to humans. Phenobarbital-mediated tumor promotion clearly occurs in mouse liver 
expressing the human CAR and PXR receptors, but, regarding both the resulting tumor 
multiplicities and tumor volume fractions, at a much lower intensity than in WT animals. The 
combination of elevated PB levels and reduced tumor burden in the hCAR/hPXR mice does 
not support the assumption that the human receptors are responsible for toxicokinetic 
alterations which might markedly reduce tumor promotion by PB between in hCAR/hPXR 
mice. Rather, toxicodynamic factors such as species differences in receptor function might 
play a role, especially since the therapeutic PB concentrations in humans are not 
substantially different from the concentrations in mice. “Humanized” mouse strains serve as 
very attractive experimental tools to investigate possible species differences in response to 
agents that exert their effects through the respective receptors. Caution is appropriate, 
however, since the human receptors function in a mouse-based heterologous system where 
gene regulatory protein interactions may differ from human hepatocytes. Nonetheless, the 
models might be very useful to analyze the effects of species-specific ligands and 
interspecies differences in receptor function. 
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Figure legends 
 
Fig. 1. Schematic delineation of the experimental setup of the tumor initiation/promotion 
study in mice with humanized CAR and PXR (hC) and wild type (WT) controls. Mice were 
injected at 6 weeks of age with a single i.p. dose of 90µg/g body weight N-
nitrosodiethylamine (DEN), followed by chronic treatment with phenobarbital (PB; 0.05% in 
the diet) for 40 weeks. The initiation/promotion experiment was conducted with15 mice per 
group. One mouse from the WT+PB group died 2 days after DEN injection, thus downsizing 
this group to 14 mice. The formation of DNA adducts following the application of DEN was 
analyzed in livers of two additional mice from each genotype 3h after DEN injection. 
 
Fig. 2. Time course of animal weight gain during the experiment (A) and relative liver weight 
(liver weight in % of total body weight) of animals at sacrifice (B). Animals were weighed at 
the respective time points; liver weight was determined at sacrifice. Mean +SEM of n=14-15 
animals per group are shown. Statistical significance (p<0.05) is indicated as follows: 
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*significant genotype effect in PB-treated mice; #significant PB treatment and genotype effect. 
(C) Histological grading of lipid droplet accumulation in liver tissue. 0, none; 1, weak; 2, 
moderate; 3, strong. 12 mice per group were analyzed. See also Figure 5 for comparison. 
Abbreviations: WT, wild type; hC, hCAR/hPXR; PB, PB-treated. 
 
Fig. 3. PB-induced expression of drug-metabolizing enzymes in WT and hCAR/hPXR mice. 
Expression at the mRNA (A) and protein levels (B) was assessed by real-time RT-PCR and 
Western blotting, respectively. (C) Densitometric analysis of protein data from (B). Gene 
expression data depict the mean +SD of n=5 randomly selected mice per group. For protein 
analysis, pooled tissue from n=3-4 different mice was used for each lane. Statistical 
significance (p<0.05) is indicated as follows: *significant genotype effect in PB-treated mice; 
#significant PB treatment and genotype effect; §significant genotype effect in untreated mice. 
Abbreviations: WT, wild type; hC, hCAR/hPXR; PB, PB-treated; STD, protein standard. 
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 Fig. 4. Analysis of tumor burden. Hepatic tumor volume fractions (A) of the different 
treatment groups and liver tumor multiplicities (B) were assessed. (C) Size class distribution 
of liver tumors. Box charts (A-B) or mean +SEM (C) of n=14-15 animals per group are shown. 
Statistical significance (p<0.05) is indicated as follows: * significant genotype effect in PB-
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treated mice; # significant PB treatment and genotype effect. Abbreviations: WT, wild type; 
hC, hCAR/hPXR; PB, PB-treated. 
 
Fig. 5. Tumor phenotype in PB-treated WT (A-C) and hCAR/hPXR (D-F) mice. 
Representative images of hematoxylin/eosin staining (A,D), immunoreactivity for the β-
catenin marker GS  (B,E), and activity of the tumor marker G6Pase (C,F) are depicted. 
Please note the accumulation of lipid droplets in tumor-surrounding normal tissue in the 
hCAR/hPXR liver visible as ‘holes’ in the slices.  
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 Fig. 6. DNA adduct formation following administration of DEN. Representative images of 
immunofluorescent staining of O6-etyhlguanine in the liver of a WT (A) and a hCAR/hPXR 
(B) mouse are shown. Please note the preferential staining of hepatocyte nuclei surrounding 
the central veins (c), whereas hepatocytes near the portal triad are not affected by the 
treatment. Staining was performed on liver slices from animals sacrificed 3h after DEN 
injection (see also scheme in Fig. 1). 
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 Fig. 7. PB levels in liver tissue. (A) Hepatic levels of PB were measured in liver tissue of WT 
and hCAR/hPXR mice at termination of the experiment after 40 weeks of PB exposure. Box 
charts (n=13-15 mice per group) are depicted. Statistical significance (p<0.05) is indicated as 
follows: * significant genotype effect in PB-treated mice. (B) Correlation of PB levels from (A) 
with hepatic tumor volume fractions (see Figure 4). The dashed line illustrates the correlation 
of the two parameters in WT mice. Abbreviations: WT, wild type; hC, hCAR/hPXR. 
 
 
Table 1.  
 
Ctnnb1 mutations in tumors from WT and hCAR/hPXR mice. 
tumor origin 
amino acid exchange WT hCAR/hPXR
D32G 1 2 
S33P 3 2 
S33A 0 1 
I35S 2 0 
S37P 4 1 
T41A 2 1 
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none detected 0 1 
Types of mutations and detected mutation frequency are shown. Total numbers of tumors 
analyzed were n=12 (WT) and n=8 (hCAR/hPXR). All analyzed tumors were from PB-treated 
mice. 
 
 
 
Table 2.  
 
Interspecies comparison of PB dose, plasma and liver levels. 
parameter mouse human 
dose [mg/kg body weight/ day] ~80 (1, estimated) 1-4 (2) 
allometrically scaled dose (exp. 0.75) --- 11.5 
plasma [µg/ml] 17.8 (3) / 15 (4) 15-70 (5) 
liver levels [µg/g] 11.9 - 20.6 (1) / 15.1 (3) 33-157 (6, estimated) 
Abbreviations : WT, wild type ; hC, humanized CAR/PXR; references: (1) present study; (2) 
Lagenstein, 1983; (3) Luisier et al., 2014; (4) Geter et al., 2014; (5) Houghton et al., 1975; (6) 
El-Masri and Portier, 1998. 
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